Skip to main content
SpringerLink
Log in

Cutaneous Melanoma

  • Chapter
PET in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 170))

Abstract

The incidence of malignant melanoma is increasing dramatically in people with light-colored skin in all parts of the world [1]. In 2004, an estimated 55,000 Americans were diagnosed with cutaneous melanoma, and 7,900 died from the disease [2]. Melanoma prognosis is linked to the stage at diagnosis. Fortunately, most new patients are diagnosed early in the clinical course of disease, when it can be cured with excision of the primary tumor and sentinel lymphadenectomy. Histologie confirmation of diagnosis and microstaging with an accurate tumor thickness are essential before embarking on treatment [3, 4]. Invasive primary melanomas to a depth of 2.0 mm or less without ulceration and negative nodal metastases are essentially curable, whereas melanomas of increasing depth become progressively less curable [4, 5]. Thus, the relationship between tumor thickness and 10-year survival rates is pivotal [5].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687–701

    PubMed  CAS  Google Scholar 

  2. Jemal A, Tiwari RC, Murray T et al (2004) American Cancer Society. Cancer statistics, 2004. Ca: a Cancer Journal for Clinicians 54:8–29

    Article  Google Scholar 

  3. Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902–908

    Article  PubMed  CAS  Google Scholar 

  4. Balch CM, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634

    PubMed  CAS  Google Scholar 

  5. Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648

    PubMed  CAS  Google Scholar 

  6. Kern KA (1991) [14C]deoxyglucose uptake and imaging in malignant melanoma. J Surg Res 50:643–647

    Article  PubMed  CAS  Google Scholar 

  7. Wahl RL, Hutchins GD, Buchsbaum DJ et al (1991) F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 67:1544–1550

    Article  PubMed  CAS  Google Scholar 

  8. Gambhir SS, Czernin J, Schwimmer J et al (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42 Suppl: lS–93S

    Google Scholar 

  9. Friedman KP, Wahl RL (2004) Clinical use of positron emission tomography in the management of cutaneous melanoma. Sem Nucl Med 34:242–253

    Article  Google Scholar 

  10. Prichard RS, Hill AD, Skehan SJ, O’Higgins NJ (2002) Positron emission tomography for staging and management of malignant melanoma. Br J Surg 89:389–396

    Article  PubMed  CAS  Google Scholar 

  11. Mijnhout GS, Hoekstra OS, van Tulder MW et al (2001) Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 91:1530–1542

    Article  PubMed  CAS  Google Scholar 

  12. Antoch G, Vogt FM, Freudenberg LS et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199–3206

    Article  PubMed  CAS  Google Scholar 

  13. Antoch G, Saoudi N, Kuehl H et al (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22:4357–4368

    Article  PubMed  Google Scholar 

  14. Schwimmer J, Essner R, Patel A et al (2000) A review of the literature for whole-body FDG-PET in the management of patients with melanoma. Q J Nucl Med 4:153–167

    Google Scholar 

  15. Macfarlane DJ, Sondak V, Johnson T, Wahl RL (1998) Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 16:1770–1776

    PubMed  CAS  Google Scholar 

  16. Wagner JD, Schauwecker D, Davidson D et al (1999) Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 17:1508–1515

    PubMed  CAS  Google Scholar 

  17. Belhocine T, Pierard G, De Labrassinne M et al (2002) Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 7:271–278

    Article  PubMed  Google Scholar 

  18. Havenga K, Cobben DC, Oyen WJ et al (2003) Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 29:662–664

    Article  PubMed  CAS  Google Scholar 

  19. Tyler DS, Onaitis M, Kherani A et al (2000) Positron emission tomography scanning in malignant melanoma. Cancer 89:1019–1025

    Article  PubMed  CAS  Google Scholar 

  20. Finkelstein SE, Carrasquillo JA, Hoffman JM et al (2004) A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 11:731–738

    Article  PubMed  Google Scholar 

  21. Crippa F, Leutner M, Belli F et al (2000) Which kind of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 41:1491–1494

    PubMed  CAS  Google Scholar 

  22. Rinne D, Baum RP, Hör G, Kaufmann R (1998) Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82:1664–1671

    Article  PubMed  CAS  Google Scholar 

  23. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL (1998) Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227:764–769

    Article  PubMed  Google Scholar 

  24. Eigtved A, Andersson AP, Dahlstrom K et al (2000) Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 27:70–75

    Article  PubMed  CAS  Google Scholar 

  25. Paquet P, Henry F, Belhocine T et al (2000) An appraisal of 18fluorodeoxyglucose positron emission tomography for melanoma staging. Dermatology 200:167–169

    Article  PubMed  CAS  Google Scholar 

  26. Swetter SM, Carroll LA, Johnson DL, Segall GM (2002) Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 9:646–653

    Article  PubMed  Google Scholar 

  27. Krug B, Dietlein M, Groth W et al (2000) Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. ActaRadiol 41:446–452

    CAS  Google Scholar 

  28. Stas M, Stroobants S, Dupont P et al (2002) 18FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 12:479–490

    Article  PubMed  CAS  Google Scholar 

  29. Fuster D, Chiang S, Johnson G et al (2004) Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 45:1323–1327

    PubMed  Google Scholar 

  30. Reinhardt MJ, Joe AY, Jaeger U et al (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24:1178–1187

    Article  PubMed  Google Scholar 

  31. Reinhardt MJ, Wiethoelter N, Matthies A et al (2006) PET recognition of pulmonary metastases on PET/ CT imaging: impact of attenuation-corrected and non-attenuation corrected PET images. Eur J Nucl Med Mol Imaging 33:134–139

    Article  PubMed  Google Scholar 

  32. Wagner JD, Schauwecker DS, Davidson D et al (2001) FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 77:237–242

    Article  PubMed  CAS  Google Scholar 

  33. Beyer T, Townsend DW, Brun T et al (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369–1379

    PubMed  CAS  Google Scholar 

  34. Schaefer NG, Hany TF, Taverna C et al (2004) Non Hodgkin lymphoma and Hodgkin’s disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 232:823–829

    Article  PubMed  Google Scholar 

  35. Wong C, Silverman DH, Seltzer M et al (2002) The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician’s perspective. Mol Imaging Biol 4:185–190

    Article  PubMed  Google Scholar 

  36. Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM (2005) Impact of 2-deoxy-2[18F] fluoro-D-glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol 7:304–308

    Article  PubMed  Google Scholar 

  37. Eschmann SM, Pfannenberg AC, Plathow C et al (2006) Vergleich von FDG-Ganzkörper-PET/CT und Ganzkörper-MRT in der Ausbreitungsdiagnostik bei Patienten mit fortgeschrittenem Melanom. Nuklearmedizin 45:A7

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pius-Hospital Klinik für Nuklearmedizin, Georgstraße 12, 26121, Oldenburg, Germany

    M. J. Reinhardt

Authors
  1. M. J. Reinhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Nuklearmedizin, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany

    Stefan Dresel

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Reinhardt, M.J. (2008). Cutaneous Melanoma. In: Dresel, S. (eds) PET in Oncology. Recent Results in Cancer Research, vol 170. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31203-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-31203-1_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31202-4

  • Online ISBN: 978-3-540-31203-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation